10 REPUBLICANS SWITCH SUPPORT TO MCCARTHY FOR U.S. HOUSE SPEAKER; VOTING CONTINUES
Amarin Corporation Announces Research Evaluating VASCEPA/VAZKEPA And Subgroups From The REDUCE-IT Landmark Outcomes Trial To Be Presented At The European Society Of Cardiology Congress
Amarin Corporation plc (NASDAQ:AMRN) today announced new supported and/or funded research on the effects of VASCEPA®/VAZKEPA (icosapent ethyl) in specific patient subgroups at increased risk of a cardiovascular (CV)